GlobeNewswire

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer

Share

Dr. Frédéric Sedel to Transition to CSO

PARIS, July 26, 2018 (GLOBE NEWSWIRE) -- MedDay, a pioneering pharmaceutical company focused on the treatment of nervous system disorders, today announces the appointment of Christian Chavy MBA as Chief Executive Officer, effective 27th August 2018.

Mr. Chavy will succeed Dr. Frédéric Sedel, CEO and Co-Founder of MedDay, who will remain in his existing role until August 27th.  Dr. Sedel will then transition to Chief Scientific Officer and continue to serve on the board of directors.

Commenting on the appointment, Catherine Moukheibir, Chairman of the board, said, "We are thrilled to have Christian take on the role of CEO at this critical time for MedDay as we execute on our confirmatory Phase III clinical trial of MD1003 in progressive MS and make preparations to become a commercial stage company." 

"On behalf of the Board of Directors, I would also like to thank Dr. Frédéric Sedel, our co-founder, who has been instrumental in building MedDay into the company that it is today and has laid the groundwork for a company that ultimately should bring innovative treatments for patients," continued Mrs. Moukheibir. "Under his leadership, MedDay has advanced our lead candidate MD1003 into late stage clinical development, including completion of a successful Phase III trial in progressive MS, and is building a pipeline of promising candidates to treat CNS diseases.  The appointment of Christian Chavy represents a continuation of this strategy. We look forward, also, to further contributions from Frédéric Sedel in his new role as Chief Scientific Officer."

Mr. Christian Chavy commented, "I am honored to be appointed CEO of MedDay.  MD1003, which has a novel mechanism of action and which has already demonstrated strong clinical activity, is positioned to transform the treatment paradigm for progressive multiple sclerosis. We look forward to completing the Phase III trial and see a clear path to approval in the major markets, including U.S. and EU. MedDay is also dedicated to finding effective treatments for severe diseases of the nervous system through our pioneering work of targeting brain metabolism."

Dr. Frédéric Sedel commented, "I am convinced that Christian Chavy has the right skill set and vision to bring MedDay to the next stage. I am very excited with my new role as company CSO which I believe is the area where I can create the most value."

Mr. Chavy is a highly accomplished pharmaceutical executive with experience in Europe and North America. Most recently, he was the CEO of Stallergenes (2014-2016) and Partner at Ares Life Sciences (2010-2014).  His career highlights include 9 years at Actelion Pharmaceuticals (2000-2009) where he was promoted to President of Global Operations, with responsibility over USA, Europe, Japan and rest of the world. Prior to joining Actelion, he was VP, Head of the reproductive health commercial unit at Serono in Geneva and Chairman of Serono's French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France.  Earlier in his career he held roles of increasing responsibility at Bristol-Myers France, SmithKline and French Laboratories, and Merck Sharpe & Dohme.

Mr. Chavy is currently chairman of the board of Ixaltis, a specialty pharmaceutical company developing innovative treatment for genitourinary tract disorders that he founded, and serves on the board of Cerenis. He is a graduate of the Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC) and the Institut de Contrôle de Gestion (ICG).

About MedDay
MedDay is a pioneering pharmaceutical company targeting brain metabolism to treat nervous system disorders. The company was founded in 2011.  The lead product, MD1003 is a formulation of high dose Pharmaceutical grade Biotin (hdPB) developed for progressive multiple sclerosis and other demyelinating diseases. The R&D pipeline also includes MD1103 in autism spectrum disorders and MD1105 in Alzheimer's disease.

MedDay explores brain metabolic pathways through its metabolomics research platform, SPECMET, which supports the discovery of additional pipeline assets. SPECMET screens cerebrospinal fluid (CSF) from patients with various Central Nervous System (CNS) disorders to identify the disrupted metabolic pathways. Compounds that are known to affect these metabolic pathways are then identified and further developed. SPECMET was developed in collaboration with the Commissariat à l'Energie Atomique (CEA) and in March 2017, MedDay acquired the health division of Profilomic SA, an innovative company formed out of the CEA in 2010, which significantly strengthened MedDay's research capabilities as the company aims to expand its pipeline.

MedDay is well funded by investors including Sofinnova Partners, InnoBio, Andera Partners and Bpifrance Large Venture. MedDay is headquartered in Paris and has a team in Boston.

For more information, please see: www.medday-pharma.com. Follow us on Twitter: @MedDayPharm.

Contact information:
MedDay Pharmaceuticals
Email: contact@medday-pharma.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meddday Pharmaceuticals via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Value Asset Management PLC Announces Launch of GBP 1 Million Equity Private Placement22.8.2019 19:09:00 CESTPress release

Value Asset Management PLC Announces Launch of GBP 1 Million Equity Private Placement London, August 22nd, 2019. Value Asset Management PLC (VAM PLC) VAM PLC, a residential property developer within the Republic of Ireland is pleased to announce the launch of an equity private placement for gross proceeds of up to GBP 1 million. The private placement will be for up to 10,000,000 new shares in the company at a value of 10p each. Burlingtons Group, headquartered in London, have been formally engaged to conduct the placing which is intended to close by October 31st, 2019. Burlingtons Group has an extensive client and contact base across the globe through its international office base and represents many high-net-worth individuals, private investment funds, developers and banks. Burlingtons Legal LLP, which is also a member of Burlingtons Group, is separately engaged by VAM PLC to act as Bond Trustee to its “Value Asset Management PLC – 6.5% Secured Corporate Bonds 31/07/23 EUR 1 A” (ISIN:

DNO ASA: FAPE01 bond buyback22.8.2019 16:35:00 CESTPress release

Oslo, 22 August 2019 - DNO ASA, the Norwegian oil and gas operator, today purchased USD 3.0 million in nominal value of FAPE01 bonds (ISIN NO0010811268) originally issued by Faroe Petroleum plc, and renamed DNO North Sea plc. The bonds were purchased at a price of 107.00. Following the bond buyback and prior cancellations due to put option exercises, USD 65.2 million in nominal value of the FAPE01 bonds remain outstanding with DNO ASA holding the balance of USD 20.6 million. The FAPE01 bonds mature on 28 April 2023. For further information, please contact: Media: media@dno.no (mailto:media@dno.no) Investors: investor.relations@dno.no (mailto:investor.relations@dno.no) Tel: +47 23 23 84 80 -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East-North Africa region and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdista

Vaisala Digital Renews Focus and Reorganizes Operations22.8.2019 16:30:00 CESTPress release

Vaisala Press Release August 22, 2019 Vaisala Digital Renews Focus and Reorganizes Operations To drive business performance and innovation speed, Vaisala Digital focuses on transportation, renewable energy, lightning, and data-driven operations, steps up its investments in development, and reorganizes its structure and operations. Vaisala sets a new direction for its digital business with investments into new assets, capabilities, and structure to develop industry leading digital solutions to support its customers to make best decisions in weather critical operations. In addition to the recently announced acquisition of Foreca’s professional B2B weather services business, Vaisala focuses on building up enhanced competences in machine learning and artificial intelligence, consolidates its data centers into two locations, and opens a new Vaisala Digital site in Keilaniemi, Espoo, to drive co-innovation with the software research and development community. “The acquisition of Foreca’s pro

Avance Gas Holding Ltd – Notice of Annual General Meeting22.8.2019 16:27:00 CESTPress release

Avance Gas Holding Ltd – Notice of Annual General Meeting Avance Gas Holding Ltd (OSE: AVANCE) announces that its 2019 Annual General Meeting will be held on September 13, 2019. A copy of the Notice of Annual General Meeting and including the Company`s Consolidated Financial Statements for 2018 can be found in the links below and on our website at www.avancegas.com. For further queries, please contact: Peder C. G. Simonsen, CFO Tel: +47 22 00 48 15 / Email: p.simonsen@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGC), and operates a fleet of fourteen modern ships For more information about Avance Gas, please visit: www.avancegas.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments AGM Notice Avance Gas Avance Gas Annual-Report-20

Stämmokommuniké från extra bolagsstämma i Vostok New Ventures Ltd22.8.2019 16:00:00 CESTPressemelding

Extra bolagsstämma i Vostok New Ventures Ltd (”Bolaget”) hölls onsdagen den 22 augusti 2019 kl. 14.00 i Advokatfirman Vinges lokaler, Stureplan 8 i Stockholm. Stockholm, Aug. 22, 2019 (GLOBE NEWSWIRE) -- På extra bolagsstämma hade aktieägarna att ta ställning till om ett nytt aktiebaserat incitamentsprogram skulle antas för vissa ledande befattningshavare och nyckelpersoner inom Vostok New Ventures-koncernen. Följande beslut fattades: Stämman beslutade, i enlighet med styrelsens förslag, att anta ett femårigt prestationsbaserat incitamentsprogram som bygger på samma ekonomiska egenskaper för deltagarna och samma kriterier för att mäta prestation som de befintliga SDB-baserade incitamentsprogrammen, men som har utformats för att minska kostnaderna såväl för Bolaget som för deltagarna. Stämman beslutade, i enlighet med styrelsens förslag, att ändra Bolagets Bye-Laws (bolagsordning), varigenom en ny aktieklass, incitamentsaktier, införs. Stämman beslutade, i enlighet med styrelsens försla